Spanish research shows that liver stiffness can predict outcomes in people co-infected with HIV and hepatitis C

Michael Carter
Published: 30 January 2013

Liver stiffness is a strong predictor of hepatic complications and all-cause mortality in people co-infected with HIV and hepatitis C virus (HCV), Spanish investigators report in the online edition of AIDS. Liver stiffness was assessed using an ultrasound-based technique called transient elastometry (FibroScan). This can assess liver stiffness, an accurate proxy for fibrosis without the need for a liver biopsy.

“We found that baseline liver stiffness was the strongest predictor of developing hepatic events and of all-cause mortality and death in HIV/HCV-coinfected patients,” write the investigators. “The strength of our study is the large size of the study population…and the long follow-up.”

The availability of safe and potent antiretroviral therapy means that the prognosis for many people with HIV is now a normal life expectancy. However, people co-infected with HIV and hepatitis C continue to have markedly elevated mortality rates and liver disease is an important cause of death in these patients.

Liver fibrosis is a predictor of the risk of liver disease and death in co-infected people. The standard assessment tool for fibrosis is liver biopsy. However, this is an invasive procedure, has a risk of complications and is unpopular with patients. Therefore, alternative tests have been developed, one of which is FibroScan. This test uses a handheld ultrasound scanning device to measure the stiffness of the liver. A liver scarred by fibrosis is stiffer than a healthy liver.

Investigators at the Hospital Carlos III in Madrid wanted to see if liver stiffness as assessed by FibroScan was a predictor of liver disease and death in their co-infected patients. FibroScan has been in routine use at their centre since 2004.

Their observational, retrospective study involved 545 co-infected patients. Most (71%) were men, their mean age was 41 years, 81% had a history of injecting drug use and 4% were also infected with hepatitis B. All but three of the participants were taking antiretroviral therapy and 88% had an undetectable viral load. The mean duration of follow-up was 71 months.

Liver stiffness below 7.5 kPa was considered to equate to the Metavir F0-F1 stages (no or very mild fibrosis); 7.5-9.4 to Metavir F2 (mild fibrosis); 9.5-12.4 kPa to Metavir 3; and above 14.5 kPa as Metavir F4. Advanced fibrosis was classified Metavir F3-F4.

The investigators explored the relationship between baseline liver stiffness and the incidence of death and liver-related events (defined as ascites – fluid in the abdominal cavity; encephalopathy – damage to the brain; oesophageal varices – enlarged veins in the oesophagus; and hepatocellular carcinoma).

Over a third of participants (34%) had advanced fibrosis at baseline. Almost two-thirds of individuals received hepatitis C therapy during follow-up and 39% achieved a sustained virological response. Twelve participants (2%) died. Four deaths were attributed to liver disease. Liver-related events occurred in 53% participants (10%).

After taking into account potential confounders, the investigators established that baseline liver stiffness was the strongest predictor of liver-complications (OR = 1.12; 95% CI, 1.08-1.16; p < 0.0001). Moreover, liver stiffness was the only factor associated with all-cause mortality (OR = 1.09; 95% CI, 1.01-1.19; p = 0.02).

Other factors associated with liver-related events were male gender (p = 0.01), CD4 cell count (p = 0.02) and glucose levels (p = 0.006).

Hepatitis C therapy that achieved a sustained virological response was protective against liver events (p = 0.01).

“Baseline liver stiffness is the strongest predictor of liver-related complications and of all-cause mortality in HIV/HCV-coinfected patients on antiretroviral therapy,” conclude the authors. “Clearance of HCV with antiviral therapy significantly reduces the risk of developing liver decompensation events in this population.”

Reference

Fernández-Montera JV et al. Liver stiffness predicts liver-related complications and mortality in HIV patients with chromic hepatitis C on antiretroviral therapy. AIDS 27, online edition, DOI: 10.1097/QAD.0b013e32835e063f, 2013.

Hepatitis information

For more information on hepatitis visit infohep.org.

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit infohep.org >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close